...
首页> 外文期刊>Canadian journal of anesthesia: Journal canadien d'anesthesie >Epinephrine does not reduce the plasma concentration of lidocaine during continuous epidural infusion in children: (L'epinephrine ne reduit pas la concentration plasmatique de lidocaine pendant une perfusion peridurale continue chez les enfants).
【24h】

Epinephrine does not reduce the plasma concentration of lidocaine during continuous epidural infusion in children: (L'epinephrine ne reduit pas la concentration plasmatique de lidocaine pendant une perfusion peridurale continue chez les enfants).

机译:连续硬膜外输注儿童期间,肾上腺素不会降低利多卡因的血浆浓度:

获取原文
获取原文并翻译 | 示例

摘要

PURPOSE: During continuous epidural anesthesia with lidocaine, plasma monoethylglycinexylidide (MEGX), an active metabolite of lidocaine, increases continuously. We assessed the effect of epinephrine on the absorption of lidocaine and the accumulation of MEGX during continuous epidural anesthesia in children. METHODS: Anesthesia was administered as an initial bolus of 5 mg*kg(-1) of 1% lidocaine solution followed by continuous infusion at 2.5 mg*kg(-1)*hr(-1). Patients in the control group (n = 8) received lidocaine alone, while patients in the epinephrine group (n = 8) received lidocaine + epinephrine (5 micro g*mL(-1)). Concentrations of lidocaine and its active metabolite, MEGX, were measured in plasma samples obtained after 15 min, 30 min, and one, two, three, four, and five hours of infusion using high-performance liquid chromatography with ultraviolet detection. RESULTS: Plasma lidocaine concentrations were higher in samples from the control group for the first hour; however, after two hours the levels were the same in all samples. Plasma MEGX levels increased continuously in both groups and were significantly higher in the control group samples. The sum of lidocaine + MEGX was higher in the control group for the first two hours but there was no significant difference between groups after three hours. CONCLUSIONS: Reduction of the potential for systemic toxicity by the addition of epinephrine to lidocaine is limited, because the reduction of the sum of the plasma concentrations of lidocaine and its active metabolite MEGX is small and limited to the initial phase of infusion.
机译:目的:在使用利多卡因连续硬膜外麻醉期间,血浆单乙基甘氨糖苷(MEGX)(一种利多卡因的活性代谢物)持续增加。我们评估了小儿连续硬膜外麻醉期间肾上腺素对利多卡因吸收和MEGX积累的影响。方法:以5 mg * kg(-1)的1%利多卡因溶液的初始推注方式进行麻醉,然后以2.5 mg * kg(-1)* hr(-1)的速度连续输注。对照组(n = 8)患者仅接受利多卡因,而肾上腺素组(n = 8)患者则接受利多卡因+肾上腺素(5 micro g * mL(-1))。使用高效液相色谱和紫外线检测技术,在输注15分钟,30分钟以及1、2、3、4和5小时后获得的血浆样品中,测定了利多卡因及其活性代谢物MEGX的浓度。结果:在第一个小时的对照组中,血浆利多卡因的浓度较高。但是,两个小时后,所有样品的水平均相同。两组血浆MEGX水平持续升高,而对照组样品中血浆MEGX水平显着升高。头两个小时,利多卡因+ MEGX的总和在对照组中较高,但三个小时后两组之间无显着差异。结论:在利多卡因中添加肾上腺素可降低全身毒性的潜力是有限的,因为利多卡因及其活性代谢物MEGX的血浆浓度总和的降低很小,并且仅限于输注的初始阶段。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号